

## REMARKS

Claims 1-16 are currently pending in this application.

Applicants have amended claims.

Applicants have amended claim 1 to more specifically describe the claimed preparations. Specifically, the preparations are able to be administered systemically.

Applicants have amended claims 5 and 6 to direct the claims to elected subject matter.

None of the amendments presented herein constitute new matter. Applicant addresses below the outstanding rejections.

## THE OBJECTIONS

The Examiner has objected to claims 5 and 6 contending that they encompass non-elected subject matter. Applicants have amended the claims to obviate this objection. Claims 10-16 stand rejected as reciting improper dependencies. Applicants have amended claims 10 and 14 to correct the dependencies of claims 10-16.

## SPECIFICATION

The Examiner has objected to the disclosure because the Specification refers to Figures 1, 2 and 3 but no Figures are with the file. Applicants enclose a set of Figures as they appeared in the application to which the pending application claims priority. Accordingly, their submission is not new matter. Further, applicants enclose a copy of a return postcard dated June 20, 2001 indicating that the complete International Application and Translation were received by the USPTO.

## THE REJECTIONS

*35 U.S.C. § 102*

Claims 1-7 and 10-16 stand rejected under 35 U.S.C. § 102(a) and (e) as being “anticipated by” Greenwood ‘735. Specifically, the Examiner contends that Greenwood ‘735 teaches an injectable, stable, immortalized, non-tumorigenic rat retinal cell line comprising the additional noted features. Applicants traverse the rejection based on the amendments and arguments presented herein.

As described in the Specification (in reference to the application from which Greenwood '735 claims priority), the prior art did not envisage the deleterious effect induced by the presence of cell aggregates in administered formulations (page 4, lines 1-5). Accordingly, the instant invention is directed to compositions free of deleterious aggregates which may be safely administered to a patient in need of such treatment. There is no suggestion in the Examiner's arguments that Greenwood '735 provided the requisite teaching of this improvement. The Examiner has not provided any evidence that the cell preparations of Greenwood '735 were formulated into a preparation capable of being administered to a patient. Applicants respectfully request that the Examiner withdraw this rejection.

Claims 1-7 and 10-16 stand rejected under 35 U.S.C. § 102(b) as being anticipated by Greenwood '139. The Examiner has cited this document as having an identical disclosure to Greenwood '735 and recites the identical reasons for its applicability. Accordingly, the applicants respectfully request that the Examiner withdraw this rejection for the same reasons as described above.

*35 U.S.C. § 103*

Claim 9 stand rejected under 35 U.S.C. § 103(a) as being unpatentable over Greenwood '735, Greenwood '624 as applied to claims 1, 3-6, 10-11 and 13-16 above and further in view of Roux. Specifically, the Examiner contends that the cited references teach an injectable, stable, immortalized, non-tumorigenic rat retinal pigment cell line comprising a heat sensitive SV40 T antigen. The Examiner contends that Roux teaches a method of making cell suspensions of adherent micro-vascular endothelial cells. Applicants traverse.

The instant claims as amended are directed to specific cellular preparations that are capable of being administered systemically. The cell suspensions noted by the Examiner were not formulated for systemic administration. In fact, there is no suggestion or motivation to formulate unaggregated cell suspensions for systemic administration. Accordingly, applicants respectfully request that the Examiner reconsider and withdraw the rejection.

*35 U.S.C. § 112, first paragraph*

Claims 10-16 stand rejected under 35 U.S.C. § 112, first paragraph as failing to comply with the enablement requirement. Specifically, the Examiner contends that claims 10-16 are directed towards a method of gene therapy. Applicants traverse.

Applicants' claimed invention is a cell preparation. Although the cells may be transfected with a gene, administration of the cell preparation does not result in the delivery of that gene to the subject's chromosome(s). Accordingly, the state of the art with respect to gene therapy has no impact on the enablement of the instant invention. Applicants respectfully request that the Examiner reconsider and withdraw the rejection.

*35 U.S.C. § 112, second paragraph*

Claim 1 stands rejected under 35 U.S.C. § 112, second paragraph. Specifically, the Examiner contends that the term "said patent" lacks antecedent basis. Applicants have amended claim 1 to recite "subject" instead of "patent" thus obviating the rejection.


Claim 8 stands rejected as because the Examiner contends it is not clear what is meant by "a nucleic acid sequence expressing an agent preventing aggregate formation or inhibiting the expression of an agent preventing the formation of aggregates". Applicants have amended the claim to recite a nucleic acid sequence expressing an agent that has the capacity to prevent aggregate formation or inhibit the expression of an agent. Applicants respectfully request that the Examiner withdraw the rejections under 35 U.S.C. § 112, second paragraph.


CONCLUSION

Applicants request consideration and allowance of the pending claims.

Respectfully submitted,

Dated: Feb. 2, 2004

  
Ivor R. Elrifi, Reg. No. 39,529  
Scott D. Miller, Reg. No. 43,803  
Attorneys for Applicants  
c/o MINTZ, LEVIN, COHN, FERRIS  
GLOVSKY AND POPEO P.C.  
Chrysler Center  
666 Third Avenue, 24<sup>th</sup> Floor  
New York, New York 10017  
Tel: (212) 935-3000  
Fax: (212) 983-3115



USPN \_\_\_\_\_ Int'l Appln No. PC7/FR99/02964 Docket No. 19904-015464 By mm/lass

Title: Mammalian Cell Preparation's Optically Transmitted

Applicant(s): Tinsit, Serge 09/868663

The following, DUE 6/21/01 at Box PCT, Assistant Commissioner for Patents, was received in the Mail Room on the date stamped hereon.

- |  |   |
|--|---|
| <input checked="" type="checkbox"/> Certificate of Mailing by Express Mail (37 CFR 1.10) Label No. <u>EL 73527623945</u> | <input checked="" type="checkbox"/> International Preliminary Examination Report                |
| <input checked="" type="checkbox"/> Check # <u>9295</u> For <u>\$4990.00</u>   | <input type="checkbox"/> Translation of Annexes to International Preliminary Examination Report |
| <input checked="" type="checkbox"/> Transmittal Letter   | <input type="checkbox"/> Preliminary Examination Report   |
| <input checked="" type="checkbox"/> International Application as Filed   | <input type="checkbox"/> Information Disclosure Statement                                       |
| <input checked="" type="checkbox"/> Translation of International Application into English                                | <input type="checkbox"/> Assignment Document with Cover Sheet                                   |
| <input checked="" type="checkbox"/> International Search Report  | <input type="checkbox"/> First Preliminary Amendment  |
| <input checked="" type="checkbox"/> Amendments to the Claims under PCT Article 19  | <input type="checkbox"/> Second or Subsequent Preliminary Amendment                             |
| <input type="checkbox"/> Translation of Amendments to the Claims under PCT Article 19                                    | <input type="checkbox"/> Substitute Specification   |
| <input type="checkbox"/> Oath or Declaration of the Inventor(s)  | <input type="checkbox"/> Change of Power of Attorney and/or Address Letter                      |
| <input checked="" type="checkbox"/> Other <u>Unlimited Resignation for Michael Wisniewsky</u>                            | <input type="checkbox"/> Verified Statement Claiming Small Entity                               |

Mailing Date June 20, 2001

REC'D PCT/PTC 20 JUN 2001

RECEIVED  
FEB 12 2004  
TECH CENTER 1600/2900

RECEIVED  
MAY 25 2004  
TECH CENTER 1600/2900